›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:TumorNext-HRD
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Konica MinoltaType:
Laboratory Developed Test
Related tests:
TumorNext-HRD is a paired tumor and germline analysis of BRCA1 and BRCA2 plus 9 additional genes in the homologous recombination repair pathway. Identifies ovarian cancer patients who are at an increased risk for other cancers. Identifies patients who have family members that may be at a significantly increased risk for cancer and clarify management recommendations.
Cancer:
Ovarian Cancer
Gene:
ATM (ATM serine/threonine kinase), BARD1 (BRCA1 Associated RING Domain 1), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CHEK2 (Checkpoint kinase 2)
See More ...
ATM (ATM serine/threonine kinase), BARD1 (BRCA1 Associated RING Domain 1), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CHEK2 (Checkpoint kinase 2), MRE11A (MRE11 homolog, double strand break repair nuclease), NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)), PALB2 (Partner and localizer of BRCA2), RAD51C (RAD51 paralog C), RAD51D (RAD51 paralog D)
Method:
Next-Generation Sequencing (NGS)
